While bigtech revenue and share prices are soaring amidst the COVID-19 pandemic, and the market value of the top players dwarfs other companies, payouts in
While bigtech revenue and share prices are soaring amidst the COVID-19 pandemic, and the market value of the top players dwarfs other companies, payouts in
Guest Column by Dr. Roya Ghafele With a rapidly growing market that offers both attractive returns on investment and the genuine ability to transform the
Approximately 54 scientists have resigned or been fired as a result of an ongoing investigation by the National Institutes of Health into the failure of NIH
The recently announced acquisition of Finjan Holdings, Inc. (NASDAQ: FNJN), a cybersecurity and patent licensing firm, by Fortress Investment Group, a division of SoftBank, is being
The China National Intellectual Property Administration (CNIPA) recently published a document that outlines its strategy to achieve super IP power status this year. The document,
Which are the world’s most innovative economies? How are they most accurately measured? According to Bloomberg’s annual Innovation Index, Germany broke South Korea’s six-year most
The U.S. Copyright Office yesterday released a report acknowledging content holders’ ineffectiveness getting online distribution platforms to remove copyrighted material that users post without permission.
Confiscating taxpayer-funded invention rights would damage the innovation ecosystem that has generated breakthrough therapies and enabled scientists to work so quickly on Covid-19. This is
This week IPwe, the company headed by former patent litigation king Erich Spangenberg, acquired ClearAccess IP, a venture-backed, Palo Alto-based IP analytics company associated through
Some experts believe the US and China heading on a collision course, defined by mutually exclusive types of technology and IP and self-reliance. Misuse has
According to the latest World Intellectual Property Organization (WIPO) data, there is only one U.S. company among the top ten PCT or Patent Cooperation Treaty
Johnson & Johnson, the pharmaceutical giant, said yesterday it is five months away from starting human trials on a COVID-19 vaccine that would be offered